Navigation Links
ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Date:10/28/2009

Clinical Pharmacology to discuss bioequivalence recommendations for oral vancomycin hydrochloride capsule drug products on August 4, 2009. The Advisory Committee was asked if the proposed guidelines are sufficient for establishing bioequivalence for generic vancomycin oral capsules. The Advisory Committee voted unanimously in favor of the component of the proposed OGD recommendation. In the event the OGD's revised approach regarding the conditions that must be met in order for a generic drug applicant to request a waiver of in-vivo bioequivalence testing for Vancocin remains in effect, the time period in which a generic competitor may enter the market would be reduced. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the OGD's March 2006 and December 2008 recommendation to determine bioequivalence to Vancocin through in-vitro dissolution testing will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the OGD in March 2006 as revised in December 2008 and voted upon by the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancocin and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for additional indications and formulations and in additional territories;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to
    '/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
2. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
4. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
5. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
8. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. ViroPharma to Present at the Natixis Bleichroeder Conference
10. ViroPharma to Present at Three Upcoming Healthcare Conferences
11. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer ... protective stent system, today announced another positive study, reinforcing MGuard,s ... evaluation by Drs. Dmitry Dratva, Yaron Almagor, Jonathan Balkin, David ... Department of Cardiology at Shaare Zedek Medical ...
... SpeechTrans, a leader in app-based multi-language translation, ... Impaired. The new app enables the hearing impaired to ... Italian and German and Mandarin Chinese without the need ... With the new app, each person can simply speak ...
Cached Medicine Technology:Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 2Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 3Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 4Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 5Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 6SpeechTrans Offers Mobile Translation App for Hearing Impaired 2
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... initiate a range of care management programs for people living ... room (ER) use, improved health and lower costs. The ... (ACHP), are part of a report that is a comprehensive ... to improve care. Care management is the coordination ...
... Factors for,Developing MS, UB Study Shows, Summary: ... (CCSVI), which has attracted global attention as possibly being correlated ... the presence of risk factors in subjects who do not ... of 252 volunteers has found an association between CCSVI and ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... fiddling with food and drink or doing some last-minute grooming, ... admit to being dangerously distracted while behind the wheel, a ... Interactive/HealthDay poll, most adults who drive on a regular ...
... or respirators put health care workers at risk of 2009 ... in the U.S., according to a study published in the ... the journal of the Society of Healthcare Epidemiology of America. ... Disease Control and Prevention (CDC), tracked 63 Southern California health ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- Women with lobular ... other forms of breast cancer to have a father who ... Swedish researchers examined the family history, pathology reports and hospital ... 2008. About 40 percent of the women had invasive ductal ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- About 40 percent ... before high school, which suggests that suicidal thoughts and behavior ... new study. As part of an ongoing survey, University ... or 19, about their history of suicide attempts. Nearly ...
Cached Medicine News:Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 2Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 4Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 2Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 3Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 4Health News:Lobular Breast Cancer Linked to Paternal Cancer History 2Health News:Many Suicidal Teens Make First Try Before High School 2
... & Lomb PMMA Anterior Chamber Intraocular Lenses ... aphakia in patients 60 years of age ... been removed by primary intracapsular cataract extraction; ... is a structural reason that the anterior ...
... STAARVISC II is a sterile nonpyrogenic, transparent ... STAARVISC II contains 12 mg/ml of high ... sodium hyaluronate dissolved in physiological saline. In ... viscosity is 105,000 cps (105 Pa s) ...
... Methylcellulose solution that is especially well suited ... incision surgery. The low molecular weight of ... minimal risk of elevated intraocular pressure. The ... of the surgical field throughout capsulorhexis and ...
... AMO Vitrax features a low ... protection and viscosity you need ... phaco and small-incision surgery. The ... anterior chamber depth for safe, ...
Medicine Products: